17
Pediatric Dosage
b
Comment
40 mg/kg/day in 4 divided doses IV • For penicillin allergic patients
• Parenteral drug of choice for treatment of
infections caused by MRSA
10 mg/kg every 12h IV
or
PO for children <12 years
• Bacteriostatic
• Limited clinical experience
• No cross-resistance with other antibiotic
classes
• Expensive
25-40 mg/kg/day in 3 divided doses IV
or
30-40 mg/kg/day in 3 divided doses PO
• Bacteriostatic
• Potential of cross-resistance and emergence
of resistance in erythromycin-resistant
strains
• Inducible resistance in MRSA
• Important option for children
N/A • Bactericidal
• Possible myopathy
N/A • Bactericidal
NOT recommended for age <8 years
e
• Bacteriostatic
• Limited recent clinical experience
8-12 mg/kg/day (based on trimethoprim
component) in either 4 divided doses IV
or 2 divided doses PO
• Bactericidal
• Limited published efficacy data
60-100,000 u/kg/dose q6h For patients with severe penicillin
hypersensitivity, use clindamycin, vancomycin,
linezolid, daptomycin, or telavancin.
125-250 mg q6h PO
50 mg/kg dose q8h IV
33 mg/kg/dose q8h IV
12.5-25 mg/kg q12h PO
10-13 mg/kg/dose q8h IV Clindamycin resistance is <1% but may be
increasing in Asia.
c
Infection due to Staphylococcus and Streptococcus species. Duration of therapy is 7 days, depending on
the clinical response.
d
Adult dosage of erythromycin ethylsuccinate is 400 mg qid PO
e
For alternatives in children see: Pickering LK. Committee on Infectious Diseases, American
Academy of Pediatrics. Antimicrobial agents and related therapy. 26th ed. Elk Grove Village, IL:
American Academy of Pediatrics; 2003.
